Company Filing History:
Years Active: 2020-2021
Title: Alex Powlesland: Innovator in Immunotherapy
Introduction
Alex Powlesland is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of immunotherapy, particularly through his innovative work on peptides and their applications in treating diseases such as cancer. With a total of four patents to his name, Powlesland's research is paving the way for new therapeutic approaches.
Latest Patents
Among his latest patents, Powlesland has developed novel peptides derived from the Transient receptor potential cation channel subfamily M member 1 (TRPM1). These peptides are designed to form complexes with recombinant MHC molecules, which are crucial for immune response. His invention also includes binding moieties that interact with these peptides and complexes, enhancing their potential as immunotherapeutic agents. Another significant patent involves peptides derived from Lengsin (LGSN), which similarly form complexes with MHC molecules and are aimed at advancing cancer treatment through immunotherapy.
Career Highlights
Throughout his career, Alex Powlesland has worked with prominent companies in the biotechnology sector, including Immunocore Limited and Adaptimmune Limited. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of his notable coworkers include Maurits Kleijnen and Alina Popa. Their collaborative efforts have further enriched the research environment and fostered innovation in immunotherapeutic solutions.
Conclusion
Alex Powlesland's work exemplifies the intersection of innovation and healthcare, particularly in the realm of immunotherapy. His patents and collaborations highlight his commitment to advancing medical science and improving treatment options for patients.